Study of Hyper-CVAD Plus Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia
Status:
Completed
Trial end date:
2014-07-01
Target enrollment:
Participant gender:
Summary
The goal of this clinical research study is to learn if intensive chemotherapy, combined with
imatinib mesylate (Gleevec, STI571) given for 8 courses over 6 months, followed by
maintenance imatinib mesylate plus chemotherapy for 2 years, followed by imatinib mesylate
indefinitely can improve Philadelphia-positive acute lymphoblastic leukemia. The safety of
this treatment will also be studied.